The pharmaceutical pipeline has rarely looked as consequential as it does in mid-2026. Several molecules approaching regulatory decisions this year are not merely incremental improvements on existing drugs, they represent categorical firsts: the first oral GLP-1, the first oral PCSK9 inhibitor, the first dual BAFF/APRIL inhibitor in a pivotal kidney disease trial. Each carries distinct IP architecture, competitive dynamics, and licensing implications that will shape deal-making well beyond their launch dates.
- Orforglipron(Eli Lilly) – Foundayo
Area: Obesity / Diabetes | Status: FDA Approved April 1, 2026
The approval of orforglipron on April 1, 2026, under the brand name Foundayo is one of the most structurally significant regulatory events in recent pharmaceutical history. It is the first non-peptide, small-molecule GLP-1 receptor agonist approved anywhere in the world, and its approval closes a chapter that began with the Gila monster-derived exenatide two decades ago.
The commercial implications are substantial. Unlike semaglutide, orforglipron can be taken without food or water timing restrictions, removing a key adherence barrier. It demonstrated approximately 12% weight loss at 72 weeks in its Phase 3 ATTAIN-1 trial. But the IP story is equally important: the patent strategy for small-molecule GLP-1 agonists is fundamentally different from peptide-based predecessors. Lilly’s portfolio covers composition of matter, methods of treatment, and formulations creating barriers that cannot simply be designed around via sequence modification, the approach competitors used to differentiate from semaglutide. Orforglipron validates a new structural class and opens development pathways for oral programs targeting GIP receptors and other metabolic GPCRs.
- CagriSema(Novo Nordisk)
Area: Obesity | Status: FDA Review Expected Late 2026
CagriSema is the first fixed-dose combination of a GLP-1 receptor agonist (semaglutide 2.4 mg) and an amylin analogue (cagrilintide 2.4 mg). Novo Nordisk filed the NDA in December 2025, and an FDA decision is anticipated late in 2026.
The efficacy signal is the strongest in obesity to date. In REDEFINE 1, patients treated with CagriSema lost an average of 20.4% of body weight at week 68, with 91.9% achieving at least 5% body weight reduction compared with 31.5% in the placebo group. If all patients stayed on treatment, the figure reached 22.7%. For patent strategists, the dual-mechanism combination creates a more complex IP landscape than a monotherapy: the combination itself, the manufacturing process for the fixed-dose formulation, and the dosing regimen are all separately protectable. The drug is not yet approved in the US or EU.
- EnlicitideDecanoate (Merck) – MK-0616
Area: Cardiovascular / Hypercholesterolemia | Status: FDA National Priority Voucher; NDA Expected 2026
Enlicitide is a novel macrocyclic peptide that inhibits PCSK9, the same target as Repatha and Praluent but in daily pill form. If approved, it will be the first oral PCSK9 inhibitor ever, a position that has been sought by cardiovascular drug developers for over a decade since injectable PCSK9 inhibitors launched.
The pivotal CORALreef Lipids trial showed enlicitide reduced LDL-C by 55.8% versus placebo at 24 weeks. The FDA awarded a Commissioner’s National Priority Voucher in December 2025, signaling the agency views this as addressing a critical unmet need. In May 2026, Merck published large-scale synthesis data in Science, addressing the manufacturing scalability question that has historically constrained macrocyclic peptide development. For IP counsel, enlicitide’s macrocyclic peptide structure sits in a chemically distinct space from both small molecules and antibodies, the patent landscape is sparse, which cuts both ways: Merck has significant white space to claim, but so do competitors who move quickly.
- SacituzumabTirumotecan/ sac-TMT (Merck & Kelun-Biotech)
Area: Oncology – NSCLC, Breast Cancer | Status: FDA Breakthrough Designation; National Priority Voucher
The antibody-drug conjugate (ADC) field has produced several approved drugs, but sac-TMT is generating unusually strong Phase 3 data. In the OptiTROP-Lung04 trial, it delivered a median progression-free survival of 8.3 months versus 4.3 months for platinum-based chemotherapy in EGFR-mutated NSCLC that progressed after TKI therapy, a hazard ratio of 0.49. The OptiTROP-Lung03 data, presented at ELCC 2026, showed a median overall survival of 20.0 months versus 13.5 months for docetaxel.
The FDA has awarded both Breakthrough Therapy Designation and a National Priority Voucher. More recently, the Phase 3 OptiTROP-Lung05 trial of sac-TMT combined with pembrolizumab met its primary endpoint in PD-L1-positive first-line NSCLC, the first Phase 3 ADC/checkpoint inhibitor combination trial to do so. For licensing teams, sac-TMT is a Kelun-Biotech asset being developed in the US by Merck, making it one of the highest-profile China-origin oncology assets currently in the US regulatory pipeline. If enacted, proposed BINSA legislation could affect how similar cross-border partnerships are evaluated.
- Povetacicept(Vertex Pharmaceuticals)
Area: Nephrology – IgA Nephropathy | Status: BLA Accepted; PDUFA Date November 30, 2026
Vertex is best known for cystic fibrosis. Povetacicept is the molecule it is betting on to establish a nephrology franchise. The FDA accepted the BLA in June 2026, assigning a PDUFA target action date of November 30, 2026 under accelerated approval.
The mechanism is genuinely novel: povetacicept is a dual inhibitor of BAFF and APRIL, the cytokines that drive B cell activation in IgA nephropathy. In the Phase 3 RAINIER trial, patients achieved a 52% reduction from baseline in urine protein-to-creatinine ratio at week 36, with a 49.8% reduction compared to placebo. It is the only BAFF+APRIL dual inhibitor in pivotal trials for multiple kidney diseases, with a parallel Phase 2/3 program in primary membranous nephropathy underway (OLYMPUS). The “pipeline in a product” characterisation from Vertex management is not marketing: if the RAINIER accelerated approval converts to full approval and the membranous nephropathy data holds, the asset covers two separate commercial markets. The IP question is whether Vertex’s dual-inhibitor design can be ring-fenced sufficiently to prevent follow-on biologics from accessing the same mechanism.
- Tavapadon(AbbVie)
Area: Neurology – Parkinson’s Disease | Status: NDA Filed September 2025; Decision Expected H1 2026
Tavapadon is a once-daily oral dopamine D1/D5 receptor partial agonist for Parkinson’s disease, a mechanistic departure from available dopamine agonists, which primarily target D2 and D3 receptors. AbbVie filed the NDA in September 2025, and a decision is expected in the first half of 2026.
The D1/D5 targeting profile is designed to deliver motor benefit while reducing the side effects, excessive daytime sleepiness, compulsive behaviour, psychosis that limit current dopamine agonists in practice. Three Phase 3 TEMPO trials showed consistent efficacy and a tolerability profile described by investigators as markedly improved. For Parkinson’s patients, who often manage complex multi-drug regimens, a once-daily oral option with a cleaner side effect profile addresses a concrete quality-of-life need. From a patent strategy perspective, AbbVie is filing into a well-established therapeutic class, which means the composition-of-matter landscape is heavily populated, the defensible space is in the specific D1/D5 selectivity claims and the formulation that enables once-daily dosing.
- Oveporexton(Jazz Pharmaceuticals)
Area: Neurology – Narcolepsy Type 1 | Status: NDA Filed; FDA Decision Expected 2026
Oveporexton is a first-in-class oral orexin receptor 2 (OX2R) agonist that works by directly restoring orexin signalling, the mechanism lost in narcolepsy type 1. Rather than simply managing symptoms, it is the first drug candidate designed to address the underlying neurological deficit of the condition, as demonstrated in the New England Journal of Medicine Phase 3 study and detailed in Jazz Pharmaceuticals’ FDA announcement.
For IP counsel, orexin receptor agonism is a mechanism class that has generated intense patent activity from multiple directions, including Jazz Pharmaceuticals, Takeda, and several academic institutions. The key question for freedom-to-operate analysis is whether the OX2R-selective agonist claims are distinct enough from broader orexin pathway patents to sustain commercial exclusivity. The market opportunity is substantial: narcolepsy type 1 is currently treated primarily with Sodium oxybate and stimulants, neither of which directly restores orexin signalling.
- Pegadricase(Selecta Biosciences / Sobi)
Area: Rheumatology – Refractory Gout | Status: Phase 3; NDA Filing Expected 2026
Pegadricase is a PEGylated recombinant uricase enzyme therapy positioned to compete with Krystexxa (pegloticase) in chronic refractory gout, targeting patients who have failed multiple prior therapies and cannot achieve adequate uric acid control. Its key differentiation is co-administration with tolerogenic nanoparticles designed to suppress anti-drug antibody formation, the primary cause of pegloticase treatment failure in clinical practice, as demonstrated in the DISSOLVE Phase 3 study and described by Selecta Biosciences.
The IP architecture here is layered: the enzyme itself, the PEGylation chemistry, and the immune tolerance induction platform are separately protectable. Selecta’s ImmTOR platform has broader applicability beyond gout and is being evaluated alongside other enzyme replacement therapies and biologics that face immunogenicity challenges. The question for licensing counsel is whether the immune tolerance platform can be licensed independently of the lead programme.
- Zenagamtide(Novo Nordisk)
Area: Obesity – Next-Generation | Status: Phase 2
While CagriSema awaits its FDA decision, Novo Nordisk is already advancing zenagamtide, its next-generation obesity candidate with a distinct mechanism from the GLP-1/amylin dual approach. Novo Nordisk has described it as part of its long-term strategy to extend its obesity leadership beyond the current incretin cycle.
Zenagamtide is earlier in development than the other molecules on this list, but it earns a place because of what it signals: the major incumbents are not resting on their GLP-1 franchises. They are building IP positions in successor mechanisms right now. For technology scouting teams, tracking Novo’s patent filings around zenagamtide’s mechanism reveals the next competitive front in metabolic disease before it becomes consensus knowledge.
- Suzetrigine/ VX-548 (Vertex Pharmaceuticals)
Area: Pain – Neuropathic | Status: FDA Approved 2025; Phase 3 Expansion Ongoing
Suzetrigine (Journavx) received FDA approval in early 2025 as the first selective NaV1.8 sodium channel blocker, a non-opioid mechanism for acute pain. Vertex is now running Phase 3 trials in diabetic peripheral neuropathy (DPN), with enrollment expected to complete by end of 2026.
The DPN data will determine whether suzetrigine becomes a single-indication drug or a platform mechanism. Diabetic peripheral neuropathy affects an estimated 50 million patients globally, is one of the most undertreated pain conditions in medicine, and currently has no approved disease-modifying therapy. If the DPN signal is positive, the patent implications are significant: Vertex will be defending composition-of-matter exclusivity while filing method-of-use claims across a broadening indication landscape. For competitors, the NaV1.8 mechanism itself is now validated, the race to design-around the Vertex composition claims is already underway at several companies.
The Pattern Across the List
Ten molecules. Five therapeutic areas. Several categorical firsts. What they share is a structural shift in how IP value is being created: not through incremental formulation improvements, but through mechanism novelty, new receptor targets, new molecular formats, new combination rationales.
The question for each asset is not just efficacy but defensibility: how long does the IP exclusivity hold, and how much of the commercial opportunity is captured before biosimilar or generic entry? For patent counsel, the recurring theme is that the most defensible positions in 2026 are system-level claims, the combination, the delivery format, the dosing regimen because composition-of-matter space in most of these therapeutic areas is increasingly crowded.
For investors, the molecules on this list are proxy bets on mechanism classes, not just individual drugs. A positive tavapadon outcome validates D1/D5 agonism as a therapeutic approach. A positive povetacicept outcome opens B cell-mediated nephropathy as a patent space. The molecule is the tip of the iceberg.
